Kymera Therapeutics Inc Forecast, price target & analysts
Kymera Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Kymera Therapeutics Inc Classifications & Recommendation:
Kymera Therapeutics Inc Price Target
| Target Price | $69.36 |
| Price | $63.37 |
| Potential |
9.45%
register free of charge
|
| Number of Estimates | 24 |
|
24 Analysts have issued a price target Kymera Therapeutics Inc 2026 .
The average Kymera Therapeutics Inc target price is $69.36.
This is
9.45%
register free of charge
$96.60
52.44%
register free of charge
$53.53
15.53%
register free of charge
|
|
| A rating was issued by 29 analysts: 28 Analysts recommend Kymera Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Kymera Therapeutics Inc stock has an average upside potential 2026 of
9.45%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 47.07 | 75.73 |
| 40.11% | 60.89% | |
| EBITDA Margin | -529.72% | -375.63% |
| 157.03% | 29.09% | |
| Net Margin | -475.59% | -328.91% |
| 154.33% | 30.84% |
25 Analysts have issued a sales forecast Kymera Therapeutics Inc 2025 . The average Kymera Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Kymera Therapeutics Inc EBITDA forecast 2025. The average Kymera Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
24 Kymera Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Kymera Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.98 | -3.47 |
| 18.25% | 16.44% | |
| P/E | negative | |
| EV/Sales | 53.58 |
24 Analysts have issued a Kymera Therapeutics Inc forecast for earnings per share. The average Kymera Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Kymera Therapeutics Inc...
Current Kymera Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 05 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Nov 05 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Nov 05 2025 |
| BTIG |
Locked
➜
Locked
|
Locked | Oct 22 2025 |
| Mizuho |
Locked
➜
Locked
|
Locked | Oct 21 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Oct 17 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Oct 01 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 05 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Nov 05 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Nov 05 2025 |
|
Locked
BTIG:
Locked
➜
Locked
|
Oct 22 2025 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Oct 21 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Oct 17 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Oct 01 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
